Phase III trial of Fianlimab (Anti-Lag-3) and Cemiplimab compared with Pembrolizumab as adjuvant therapy in patients with completely resected high-risk melanoma
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: REGENERON PHARMACEUTICALS, INC.
- Phase: III
- Execution start: 07/06/2023
- End of execution: 30/09/2030
- IP: JAVIER VALDIVIA BAUTISTA
